Treatment of anxiety and depressive disorders in patients with cardiovascular disease
- PMID: 15087342
- PMCID: PMC390215
- DOI: 10.1136/bmj.328.7445.939
Treatment of anxiety and depressive disorders in patients with cardiovascular disease
Abstract
What role do selective serotonin reuptake inhibitors have in treating psychiatric morbidity in patients with cardiovascular disease? This review discusses the safety and efficacy of various antidepressants in this group of patients and their potential for improving cardiovascular outcomes
References
-
- Frasure-Smith N, Lesperance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91: 999-1005. - PubMed
-
- Davies SJ, Ghahramani P, Jackson PR, Noble TW, Hardy PG, Hippisley-Cox J, et al. Association of panic disorder and panic attacks with hypertension. Am J Med 1999;107: 310-6. - PubMed
-
- Kawachi I, Sparrow D, Vokonas PS, Weiss ST. Symptoms of anxiety and risk of coronary heart disease. The normative aging study. Circulation 1994;90: 2225-9. - PubMed
-
- Lehnert H, Lombardi F, Raeder EA, Lorenzo AV, Verrier RL, Lown B, et al. Increased release of brain serotonin reduces vulnerability to ventricular fibrillation in the cat. J Cardiovasc Pharmacol 1987;10: 389-97. - PubMed
-
- Richerson GB, Wang W, Tiwari J, Bradley SR. Chemosensitivity of serotonergic neurons in the rostral ventral medulla. Respir Physiol 2001;129: 175-89. - PubMed